Hormonal
SGLT-2 inhibitors and GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) in Type 2 Diabetes patients, with SGLT-2i showing specific superiority for kidney outcomes.
For Type 2 Diabetes patients with heart or kidney risks, prioritize SGLT-2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. SGLT-2 inhibitors are particularly strong for protecting the kidneys.
Investigators found that both the SGLT-2i and GLP-1 RA medications were effective in reducing all-cause death, cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, and ESKD... SGLT-2i medications were shown to be superior to other medications in reducing end-stage kidney disease.
Why this rating
Based on 821 trials, 471,815 patients, using GRADE assessment.
Source
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Antonio Ceriello et al. · Cardiovascular Diabetology · 2023
DOI 10.1186/s12933-023-01993-3
More from this paper
- Network meta-analyses (NMA) provide superior clinical utility for diabetes management compared to standard pairwise meta-analyses by simultaneously comparing multiple treatments using both direct and indirect evidence.Strong
- Tirzepatide (a dual GIP/GLP-1 receptor agonist) facilitates the largest reduction in body weight and increases in health-related quality of life (QoL) among Type 2 Diabetes medications.Strong
- Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduces hospital admissions for heart failure and end-stage kidney disease, and decreases mortality in Type 2 Diabetes patients with Chronic Kidney Disease (CKD).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →